Harvard Bioscience Inc (HBIO) Dividend History

Harvard Bioscience Inc (HBIO) is a global developer and manufacturer of biomedical research and clinical products. The company offers equipment and tools used in life sciences research, including instruments for cell analysis, laboratory automation, and tissue culture. Harvard Bioscience serves academic, government, and industry customers by supporting advances in biomedical research and drug development.

84 October Hill Rd, Holliston, MA, 01746
Phone: (508) 893-8999
Website: https://www.harvardbioscience.com

Dividend History

Harvard Bioscience Inc currently does not pay dividends

Company News

  • Harvard Bioscience Appoints John Duke to Board of Directors

    Harvard Bioscience announced the appointment of John Duke to its board of directors and the retirement of Thomas Loewald. The company also reported its first quarter 2025 financial results.

    GlobeNewswire Inc.
    Featured Companies: GLW
  • Harvard Bioscience (HBIO) Q1 Earnings Match Estimates

    Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0% and 4.92%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: MTD
  • Why Harvard Bioscience Stock Rose This Week

    The company reported improved revenue in Q1.

    The Motley Fool
  • Top 5 Health Care Stocks That May Fall Off A Cliff This Quarter

    The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70. Here’s the latest list of major overbought players in this sector. Novo Nordisk A/S (NYSE: NVO) Novo Nordisk raised its 2023 operating profit and sales growth expectations supported by stronger expected sales of its Wegovy (semaglutide) obesity drug. The company’s stock has a 52-week high of $169.88 . RSI ...

    Benzinga
    Featured Companies: EYEN
Page data last updated 07/22/2025 23:40:49 UTC